Core Insights - Lunan Pharmaceutical has maintained continuous operation of several production lines for three years, indicating strong market demand and production efficiency [2][3] - The company has achieved significant milestones in research and development, with a focus on optimizing production processes and enhancing product quality [3][4] - Lunan Pharmaceutical is transitioning from a pharmaceutical manufacturer to a full industry chain player, emphasizing collaboration and innovation across the supply chain [5][6] - The company has experienced substantial growth in international business, with a ninefold increase in sales from 2 billion to 20 billion over a decade, expanding its global footprint [7][8][9] Production and Market Position - Certain production lines, such as the one for potassium clavulanate, have reached a capacity of 1,500 tons per year, accounting for nearly one-third of global usage, positioning Lunan as a market leader [2] - The company has developed a domestic first for a composite film production line for traditional Chinese medicine oral liquids, replacing fragile glass bottles with food-grade aluminum-plastic films [3] Research and Development - Lunan Pharmaceutical has invested over 10 billion in R&D over the past decade, establishing multiple national and provincial innovation platforms to support drug development [4] - The company has achieved 40 breakthroughs in R&D, including significant cost savings in production processes, demonstrating a commitment to continuous improvement [3][4] International Expansion - The company has successfully transitioned from exporting raw materials to finished formulations, increasing profit margins significantly [7] - Lunan Pharmaceutical has registered 72 formulation products in 129 countries, establishing a strong international presence and partnerships with over 200 global companies [8][9]

Core Viewpoint - The article highlights the significant achievements and innovations of Lunan Pharmaceutical, emphasizing its commitment to quality and technological advancement in the pharmaceutical industry, positioning it as a leading brand in Shandong and beyond [1][2][5]. Group 1: Company Achievements - Lunan Pharmaceutical has achieved a production capacity of 1,500 tons of clavulanate potassium annually, accounting for nearly one-third of global demand, making it the world's largest producer [2]. - The company has invested over 10 billion yuan in research and development over the past decade, resulting in numerous successful products and innovations [4]. - Lunan Pharmaceutical ranked 13th in the "2025 China Pharmaceutical R&D Comprehensive Strength Ranking" and has established multiple national and provincial-level innovation platforms [5]. Group 2: Product Development and Innovation - The company has seen a surge in new product launches, with an expected 40 to 50 products entering production this year, particularly in the innovative drug sector [5]. - Lunan Pharmaceutical's first antibody-based biopharmaceutical, Yilidali Rituximab Injection, was approved after 15 years of development, marking a significant milestone in its product portfolio [6][8]. - The company has optimized production processes, saving approximately 4 million yuan annually through continuous research breakthroughs [2]. Group 3: International Expansion - Lunan Pharmaceutical's international business has grown tenfold from 200 million yuan in 2014 to 2 billion yuan in 2024, with 72 formulation products approved in 129 countries and regions [10][12]. - The company has transitioned from exporting raw materials to exporting formulations, increasing profit margins by 5 to 7 times [11]. - Lunan Pharmaceutical has established partnerships with over 200 global companies and is actively expanding its presence in emerging markets across Asia, Africa, and Eastern Europe [12].